Compare Stocks → Urgent: Protect Your Investments from a Chinese Invasion (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATRANASDAQ:CLLSNASDAQ:OYSTNASDAQ:PRTONASDAQ:RCEL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$0.69-1.1%$0.74$0.20▼$3.08$70.59M0.713.17 million shs921,486 shsCLLSCellectis$2.67$2.74$0.96▼$3.77$148.40M3.1342,338 shs29,121 shsOYSTOyster Point Pharma$11.17$11.15$3.46▼$19.00$299.85M1.31212,171 shs330 shsPRTOProteon Therapeutics$4.00-3.6%$19.37$0.22▼$3.94$88.72M0.61.11 million shs68,449 shsRCELAVITA Medical$16.03-2.8%$16.78$9.16▼$21.70$412.13M1.39165,940 shs61,435 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics+5.90%-2.78%-1.55%+27.62%-75.52%CLLSCellectis+6.80%+8.98%-1.84%-21.24%+31.20%OYSTOyster Point Pharma0.00%0.00%0.00%0.00%0.00%PRTOProteon Therapeutics+0.25%0.00%-4.99%+112.77%+20.85%RCELAVITA Medical+3.19%+2.17%-9.84%+15.63%+21.95%Urgent: Protect Your Investments from a Chinese Invasion (Ad)An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics3.9927 of 5 stars3.02.00.04.71.12.51.3CLLSCellectis2.9015 of 5 stars3.53.00.00.03.12.50.6OYSTOyster Point PharmaN/AN/AN/AN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARCELAVITA Medical1.8062 of 5 stars3.53.00.00.02.70.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics2.00Hold$28.003,942.74% UpsideCLLSCellectis3.00Buy$11.00311.99% UpsideOYSTOyster Point PharmaN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/ARCELAVITA Medical3.00Buy$27.8073.42% UpsideCurrent Analyst RatingsLatest PRTO, OYST, CLLS, ATRA, and RCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/23/2024RCELAVITA MedicalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$19.00 ➝ $21.002/23/2024RCELAVITA MedicalCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $25.001/19/2024RCELAVITA MedicalCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$20.00 ➝ $22.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$63.57M1.11N/AN/A$1.33 per share0.52CLLSCellectis$25.73M5.77N/AN/A$2.76 per share0.97OYSTOyster Point Pharma$24.54M12.22N/AN/A$3.80 per share2.94PRTOProteon TherapeuticsN/AN/AN/AN/A($0.06) per shareN/ARCELAVITA Medical$50.14M8.22N/AN/A$1.92 per share8.35Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$228.30M-$2.78N/AN/AN/A-6,390.31%-783.31%-104.24%4/3/2024 (Estimated)CLLSCellectis-$106.14M-$1.67N/A∞N/A-346.65%-73.03%-32.22%4/3/2024 (Estimated)OYSTOyster Point Pharma-$100.66M-$6.65N/AN/AN/A-901.99%-490.33%-108.29%N/APRTOProteon Therapeutics-$20.73M-$1.15N/AN/AN/AN/AN/A-118.68%N/ARCELAVITA Medical-$35.38M-$1.40N/AN/AN/A-70.56%-54.80%-38.08%5/9/2024 (Estimated)Latest PRTO, OYST, CLLS, ATRA, and RCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024N/AATRAAtara BiotherapeuticsN/A-$0.48-$0.48N/AN/AN/A2/22/2024Q4 2023RCELAVITA Medical-$0.34-$0.28+$0.06-$0.28$14.10 million$14.20 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AOYSTOyster Point PharmaN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/ARCELAVITA MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A1.501.42CLLSCellectis0.572.202.20OYSTOyster Point Pharma8.493.353.11PRTOProteon TherapeuticsN/A5.985.98RCELAVITA Medical0.817.887.46OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%CLLSCellectis63.90%OYSTOyster Point Pharma96.70%PRTOProteon Therapeutics23.03%RCELAVITA Medical27.66%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.50%CLLSCellectis16.41%OYSTOyster Point Pharma17.90%PRTOProteon Therapeutics45.70%RCELAVITA Medical1.96%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics334101.92 million97.34 millionOptionableCLLSCellectis23155.58 million46.46 millionOptionableOYSTOyster Point Pharma30326.84 million22.04 millionNot OptionablePRTOProteon Therapeutics1722.18 millionN/ANot OptionableRCELAVITA Medical20725.71 million25.20 millionOptionablePRTO, OYST, CLLS, ATRA, and RCEL HeadlinesSourceHeadlineRCEL Apr 2024 22.500 putfinance.yahoo.com - March 16 at 8:16 AMRCEL Oct 2024 17.500 putfinance.yahoo.com - March 16 at 8:16 AMAVITA Medical: Unconvincing Growth Amid Fierce Competition In The Burn Care Sectorseekingalpha.com - March 5 at 2:05 PMAVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplementfinance.yahoo.com - February 29 at 4:15 PMAVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplementglobenewswire.com - February 29 at 4:02 PMAVITA Medical to Present at TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 29 at 9:00 AMFY2024 EPS Estimates for AVITA Medical, Inc. (NASDAQ:RCEL) Cut by Cantor Fitzgeraldmarketbeat.com - February 29 at 8:41 AMAVITA Medical (RCEL) Price Target Increased by 6.80% to 26.69nasdaq.com - February 26 at 10:49 PMBRIEF-Seatrium Limited Says FY Revenue S$7.3 Blnsg.finance.yahoo.com - February 26 at 1:49 AMAvita Medical Poised for Growth: Strong Q4 Performance and Promising 2024 Outlook Reinforce Buy Ratingmarkets.businessinsider.com - February 23 at 5:44 PMAVITA Medical, Inc. (NASDAQ:RCEL) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 23 at 12:43 PMAVITA Medical to Host Investor Webinar Briefingglobenewswire.com - February 23 at 9:01 AMArdelyx Posts Q4 Loss, Joins MercadoLibre, Booking Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Sessionmsn.com - February 23 at 7:35 AMBuy Rating Affirmed for Avita Medical on Strong Financials and Expansive Growth Strategymarkets.businessinsider.com - February 23 at 2:34 AMAVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidanceglobenewswire.com - February 22 at 4:01 PMAVITA Medical Q4 2023 Earnings Previewmsn.com - February 21 at 2:21 PMRCEL Mar 2024 15.000 callfinance.yahoo.com - February 17 at 12:44 PMAVITA Medical, Inc. (NASDAQ:RCEL): Are Analysts Optimistic?finance.yahoo.com - February 7 at 3:22 PMAVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Resultsfinance.yahoo.com - February 1 at 7:40 PMAvita Medical Poised for Growth: Buy Rating and $40 Price Target Justified by Strategic Partnerships and Positive Financial Indicatorsmarkets.businessinsider.com - January 12 at 12:45 AMAVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientificfinance.yahoo.com - January 10 at 6:49 PMAVITA Medical Inc (RCEL) rating initates by Cantor Fitzgeraldknoxdaily.com - January 1 at 2:07 PMAVITA Medical Positioned For Stellar 2024 With Skin Repair Innovation Momentumseekingalpha.com - December 19 at 11:15 PMAvita Medical cuts 2023 commercial revenue guidance on longer hospital approval timelinesmsn.com - November 20 at 11:31 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAtara BiotherapeuticsNASDAQ:ATRAAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.CellectisNASDAQ:CLLSCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Oyster Point PharmaNASDAQ:OYSTOyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.Proteon TherapeuticsNASDAQ:PRTOProteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.AVITA MedicalNASDAQ:RCELAVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.